EGFRvIII Peptide Nanocapsules and Bevacizumab Nanocapsules: A Nose-To-Brain Multitarget Approach Against Glioblastoma
Aline de Cristo Soares Alves, Vladimir Lavayen, Amanda de Fraga Dias, Franciele Aline Bruinsmann, Juliete Nathali Scholl, Rodrigo Cé, Fernanda Visioli, Ana Maria Oliveira Battastini, Sı́lvia Stanisçuaski Guterres, Fabrício Figueiró, Adriana Raffin Pohlmann
Abstract
Aim: To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III. Materials & methods: Nanocapsules were prepared, physicochemical characterized and intranasally administered to rats. Parameters such as tumor size, histopathological characteristics and infiltration of CD8+ T lymphocytes were evaluated. Results: The strategy of treatment resulted in a reduction of 87% in the tumor size compared with the control group and a higher infiltration of CD8+ T lymphocytes in tumoral tissue. Conclusion: The block of two different molecular targets using nose-to-brain delivery represents a new and promising approach against glioblastoma.